Treatment of hereditary angioedema with icatibant: Efficacy in clinical trials versus effectiveness in the real-world setting

Allergy and Asthma Proceedings

Volumn 35, Issue 5, 2014, Pages 377-381

  Maurer, Marcus ^a   Longhurst, Hilary J ^b   Fabien, Vincent ^c   Li, H Henry ^d   Lumry, William R ^e   Aberer, W ^f   Bygum, A ^f   Blanchard Delauny, C ^f   Boccon Gibod, I ^f   Bouillet, L ^f   Fain, O ^f   Gompel, A ^f   Launay, D ^f   Maillard, H ^f   Ollivier, Y ^f   Bork, K ^f   Greve, J ^f   Maurer, M ^f   Psarros, F ^f   Toubi, E ^f   Arcoleo, F ^f   Bova, M ^f   Montinaro, V ^f   Marone, G ^f   Zanichelli, A ^f   Caballero, M T ^f   Guilarte, M ^f   Hernandez, D ^f   Baeza, M L ^f   Helbert, M ^f   Longhurst, H ^f   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c Shire   (Switzerland)

^d Institute for Asthma and Allergy   (United States)

^e 5AARA Research Center   (United States)

^f NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ICATIBANT; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST;

ANGIONEUROTIC EDEMA; CONFERENCE PAPER; DRUG EFFICACY; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; TIME TO TREATMENT; TREATMENT OUTCOME; ADOLESCENT; ADULT; ANALOGS AND DERIVATIVES; ANGIOEDEMAS, HEREDITARY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; ANGIOEDEMAS, HEREDITARY; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONISTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907044494     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2014.35.3780     Document Type: Conference Paper

References (15)

1. Longhurst H and Cicardi M. Hereditary angio-oedema. Lancet 379:474-481, 2012.
2. Bernstein JA. HAE update: Epidemiology and burden of disease. Allergy Asthma Proc 34:3-6, 2013.
3. Caballero T, Aygören-Pürsün E, Bygum A, et al. The humanistic burden of hereditary angioedema: Results from the Burden of Illness Study in Europe. Allergy Asthma Proc 35:47-53, 2014.
4. Bork K and Davis-Lorton M. Overview of hereditary angioedema caused by C1-inhibitor deficiency: Assessment and clinical management. Eur Ann Allergy Clin Immunol 45:7-16, 2013.
5. Bowen T, Cicardi M, Farkas H, et al. International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 6:24, 2010.
6. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group. Allergy 67:147-157, 2012.
7. Craig T, Aygören-Pürsün E, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 5:182-199, 2012.
8. Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract 1:458-467, 2013.
9. Shire. Firazyr Summary of Product Characteristics. Available at: http://www.ema.europa.eu/ema/index.jsp?curl-ages/medicines/human/medicines/000899/human-med-000793.jsp&murl-menus/medicines/medicines.jsp&mid-WC0b01ac058001d124. Last update 2014. Accessed July 29, 2014.
10. Shire. Firazyr US Prescribing information. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction-Search.Label-ApprovalHistory#labelinfo. Last update 2013. Accessed July 29, 2014.
11. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532-541, 2010.
12. Lumry WR, Li HH, Levy RJ, et al. Randomized placebocontrolled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: The FAST-3 trial. Ann Allergy Asthma Immunol 107:529-537, 2011.
13. Maurer M, Aberer W, Bouillet L, et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One 8:e53773, 2013.
14. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363:513-522, 2010.
15. Zuraw BL and Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 125:938.e1-e7, 2012.